About Hikma
Hikma is a company based in Amman (Jordan) founded in 1978. It operates as a Direct-to-Consumer (D2C), and Professional Services. The company has 9,500 employees as of December 31, 2024. Hikma has completed 6 acquisitions, including Custopharm, EIMC Pharmaceuticals and Medlac Pharma. Hikma offers products and services including Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
- Headquarter Amman, Jordan
- Employees 9500 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hikma Pharmaceuticals Plc
-
Annual Revenue
$3.07 B (USD)5.81as on Dec 31, 2024
-
Net Profit
$352.01 M (USD)83.81as on Dec 31, 2024
-
EBITDA
$788.34 M (USD)14.68as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
9500
as on Dec 31, 2024
-
Investments & Acquisitions
Custopharm
& 5 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hikma
Hikma is a publicly listed company on the LSE with ticker symbol HIK in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Hikma
Hikma offers a comprehensive portfolio of products and services, including Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
High-quality injectable medicines are produced for global markets.
Biosimilar products are developed for bone health treatment.
Pain management injection is offered in prefilled syringes.
Unlock access to complete
Unlock access to complete
Software Development Team
56 people
Leadership Team
30 people
Operations Team
25 people
Product Management Team
19 people
Legal and Compliance
14 people
Human Resources and Administration
10 people
Sales and Marketing
7 people
Senior Team
6 people
Unlock access to complete
Funding Insights of Hikma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Hikma
Hikma has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Custopharm, EIMC Pharmaceuticals and Medlac Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer and manufacturer of pharmaceutical parental products
|
2008 | ||||
|
Employee benefits administration and insurance products are provided.
|
2005 | ||||
|
Manufacturer of oncology drugs
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Hikma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hikma Comparisons
Competitors of Hikma
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hikma
Frequently Asked Questions about Hikma
When was Hikma founded?
Hikma was founded in 1978.
Where is Hikma located?
Hikma is headquartered in Amman, Jordan.
Who is the current CEO of Hikma?
Riad Mishlawi is the current CEO of Hikma.
How many employees does Hikma have?
As of Dec 31, 2024, the latest employee count at Hikma is 9,500.
What is the annual revenue of Hikma?
Annual revenue of Hikma is $3.07B as on Dec 31, 2024.
What does Hikma do?
Hikma Pharmaceuticals PLC is engaged in the development, manufacturing, and distribution of high-quality medicines across North America, MENA, and Europe. Operations are focused on generics, specialty pharmaceuticals, and injectables. Solutions are provided through strategic acquisitions, expanded manufacturing capabilities, and investment in research and development. The company is committed to sustainability and advancing health by ensuring access to medicines, maintaining product quality, and upholding ethical standards. Various therapeutic areas are addressed to improve patient outcomes worldwide.
What products or services does Hikma offer?
Hikma offers Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
Is Hikma publicly traded?
Yes, Hikma is publicly traded on LSE under the ticker symbol HIK.
How many acquisitions has Hikma made?
Hikma has made 6 acquisitions, including Custopharm, EIMC Pharmaceuticals, and Medlac Pharma.
What is Hikma's ticker symbol?
The ticker symbol of Hikma is HIK on LSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.